525 related articles for article (PubMed ID: 29689073)
1. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
3. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
4. Decreasing Hepatitis C Virus Infection in Thailand in the Past Decade: Evidence from the 2014 National Survey.
Wasitthankasem R; Posuwan N; Vichaiwattana P; Theamboonlers A; Klinfueng S; Vuthitanachot V; Thanetkongtong N; Saelao S; Foonoi M; Fakthongyoo A; Makaroon J; Srisingh K; Asawarachun D; Owatanapanich S; Wutthiratkowit N; Tohtubtiang K; Yoocharoen P; Vongpunsawad S; Poovorawan Y
PLoS One; 2016; 11(2):e0149362. PubMed ID: 26871561
[TBL] [Abstract][Full Text] [Related]
5. A multicentre, observational study on demographic and disease characteristics of patients seeking care for chronic hepatitis C in Belgium in 2016.
Bourgeois S; Mulkay JP; Lasser L; Robaeys G; Bastens B; Delwaide J; Pollet S; Van den Enden M
Acta Gastroenterol Belg; 2019; 82(1):43-52. PubMed ID: 30888753
[TBL] [Abstract][Full Text] [Related]
6. The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms.
Willemse SB; Razavi-Shearer D; Zuure FR; Veldhuijzen IK; Croes EA; van der Meer AJ; van Santen DK; de Vree JM; de Knegt RJ; Zaaijer HL; Reesink HW; Prins M; Razavi H
Neth J Med; 2015 Nov; 73(9):417-31. PubMed ID: 26582807
[TBL] [Abstract][Full Text] [Related]
7. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
[TBL] [Abstract][Full Text] [Related]
8. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
[TBL] [Abstract][Full Text] [Related]
9. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis G; Razavi H; Hatzakis A
J Gastroenterol Hepatol; 2017 Feb; 32(2):466-472. PubMed ID: 27403912
[TBL] [Abstract][Full Text] [Related]
10. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
[TBL] [Abstract][Full Text] [Related]
11. Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid.
Kabiri M; Chhatwal J; Donohue JM; Roberts MS; James AE; Dunn MA; Gellad WF
Healthc (Amst); 2017 Sep; 5(3):105-111. PubMed ID: 27932263
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
European Union HCV Collaborators
Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
Papatheodoridis GV; Hatzakis A; Cholongitas E; Baptista-Leite R; Baskozos I; Chhatwal J; Colombo M; Cortez-Pinto H; Craxi A; Goldberg D; Gore C; Kautz A; Lazarus JV; Mendão L; Peck-Radosavljevic M; Razavi H; Schatz E; Tözün N; van Damme P; Wedemeyer H; Yazdanpanah Y; Zuure F; Manns MP
J Viral Hepat; 2018 Mar; 25 Suppl 1():6-17. PubMed ID: 29508946
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain.
Crespo J; Cuadrado A; Perelló C; Cabezas J; Llerena S; Llorca J; Cedillo S; Llop E; Escudero MD; Hernández Conde M; Puchades L; Redondo C; Fortea JI; Gil de Miguel A; Serra MA; Lazarus JV; Calleja JL
J Viral Hepat; 2020 Apr; 27(4):360-370. PubMed ID: 31755634
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
16. Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population.
Ethgen O; Sanchez Gonzalez Y; Jeanblanc G; Duguet A; Misurski D; Juday T
J Med Econ; 2017 Feb; 20(2):162-170. PubMed ID: 27590836
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.
Benzaken AS; Girade R; Catapan E; Pereira GFM; Almeida EC; Vivaldini S; Fernandes N; Razavi H; Schmelzer J; Ferraz ML; Ferreira PRA; Pessoa MG; Martinelli A; Souto FJD; Walsh N; Mendes-Correa MC
Braz J Infect Dis; 2019; 23(3):182-190. PubMed ID: 31145876
[TBL] [Abstract][Full Text] [Related]
18. A micro-elimination approach to addressing hepatitis C in Turkey.
Idilman R; Razavi H; Robbins-Scott S; Akarca US; Örmeci N; Kaymakoglu S; Aygen B; Tozun N; Güner R; Bodur H; Lazarus JV
BMC Health Serv Res; 2020 Mar; 20(1):249. PubMed ID: 32209103
[TBL] [Abstract][Full Text] [Related]
19. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.
Gentile I; Maraolo AE; Niola M; Graziano V; Borgia G; Paternoster M
Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1227-1234. PubMed ID: 27607920
[TBL] [Abstract][Full Text] [Related]
20. A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System.
Nguyen JT; Rich JD; Brockmann BW; Vohr F; Spaulding A; Montague BT
J Urban Health; 2015 Aug; 92(4):635-49. PubMed ID: 25828149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]